[1] 2019-nCoV 감염이 확진된 환자에게는 조기에 항바이러스제 치료를 고려한다.
[2] 2019-nCoV에 감염이 의심되는 환자가 폐렴 소견을 보이는 경우 경험적으로 항바이러스제 치료를 고려할 수 있다.
[3] 2019-nCoV 감염 의심 환자에서 유전자 검사 결과가 48시간 간격으로 음성인 경우 항바이 러스제 치료 중단을 고려한다.
[4] 항바이러스제 치료로 Kaletra (lopinavir/ritonavir) 고려한다 (성인 용량/용법: 400mg/100mg(2T) po q12hr). 소아의 경우 시럽제를 사용한다 (소아는 소아 용량/용법을 참조한다).
[5] 항바이러스제 치료로 Kaletra (lopinavir/ritonavir) + interferon 병합 요법도 고려할 수 있다.
[6] 항바이러스제는 10-14일 투여를 권하며, 환자 상태에 따라 조절 가능하다.
|
*참고 문헌
Chan KS, Lai ST et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003 Dec;9(6):399-406
Tsang K et al. SARS: pharmacotherapy. Respirology. 2003 Nov;8 Suppl:S25-30.
Yastag B. Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS. JAMA. 2003 Oct 1;290(13):1695-6.
Chu CM et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59(3): 252–56.
Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318:719-25
Cheng VC et al. Medical treatment of viral pneumonia including SARS in immunocompetent adult. J Infect. 2004 Nov;49(4):262-73.
Chau TN et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004 Feb;39(2):302-10.
Chen XP et al. Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome. Clin Infect Dis. 2004 Apr 1;38(7):1030-2. Epub 2004 Mar 15.
Fujii T et al. Current concepts in SARS treatment. J Infect Chemother. 2004 Feb;10(1):1-7.
Shigeta S.,Yamase T. Current status of anti-SARS agents. Antivir Chem Chemother. 2005;16(1):23-31.
Lin C, Tsai F, Tsai C, Lai C, Wan L, Ho T, et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005;68:36-42
Savarino A. Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza. J Clin Virol. 2005 Nov;34(3):170-8
Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):583-91.
Stockman LJ et al. SARS: systematic review of treatment effects PLoS Med. 2006 Sep;3(9):e343.
Tai DY. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore. 2007 Jun;36(6):438-43.
Wong SS et al. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother. 2008 Sep;62(3):437-41.
Hui DS et al. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med. 2014 May;20(3):233-41.
Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung S. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J Med Chem. 2016;59:6595-628.
Dyaer M et al. Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study. Arch Clin Infect Dis. 2017 October; 12(4):e13823.
Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 2018; 19: 81.
Sheahan T, Sims A, Leist S, Schäfer A, Won J, Brown A, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222
上海药物所和上海科技大学联合发现一批可能对新型肺炎有治疗作用的老药和中药. People's Republic of China: Chinese Academy of Sciences. 2020년 1월 25일.
|